Cheryl Ho, MD, FRCP(C)
Cheryl Ho, MD, FRCPC
Clinical Associate Professor
University of British Columbia
British Columbia Cancer
Cheryl Ho, MD is a medical oncologist at BC Cancer and Clinical Associate Professor at the University of British Columbia. Her clinical practice focuses on thoracic and head & neck malignancies. Dr. Ho evaluates the impact of therapies proven in clinical trials in the real world through population-based analysis. Her current focus is on developing a learning health care system with a real-world data evidence-generation framework to inform healthcare decision-makers.
Barbara Melosky, MD, FRCP(C)
Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group.
Her main focus of clinical trials is on EGFR inhibitors; she is published in this area and is considered a national and international expert. Dr. Melosky has chaired the Canadian Lung Cancer Conference for the last 12 years, which is attended by over 350 participants. She chairs and organized the multi-disciplinary Lung Cancer Journal Club three times yearly. She is chair and created the British Columbia Lung Cancer Biobank.
She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.
Randeep Sangha, MD, FRCPC
Medical Oncologist, Cross Cancer Institute
Associate Professor, University of Alberta
Dr. Sangha is an Associate Professor in the Department of Oncology at the University of Alberta and Medical Oncologist at the Cross Cancer Institute, Edmonton, AB. He is the Provincial Lead for the Alberta Lung Cancer Program.
Dr. Sangha received his medical degree at the University of Alberta and subsequently specialized in Internal Medicine and Medical Oncology. He completed two years of post-fellowship training in thoracic oncology at the University of California, Davis Comprehensive Cancer Center.
His academic, clinical, and educational activities revolve around thoracic and hematological malignancies. He is also experienced in Investigational New Drug (Phase I) development and is actively involved in the Phase I clinical trials program at the Cross Cancer Institute.
Devin Schellenberg, MD, FRCS(C)
Clinical Associate Professor – UBC
Department Head, Radiation Oncology
BC Cancer – Surrey Centre
Dr. Devin Schellenberg completed medical school and Residency at the University of BC and University of Toronto. He went onto a Fellowship at Stanford University and has been the Department Head of Radiation Oncology at the BC Cancer Surrey Centre for the past 4 years. He chairs the Lung Radiation Oncology working group with CCTG and is a founding member of CAPRI (Canadian Pulmonary Radiotherapy Investigators Group).
He has been a leader in BC Cancer’s Stereotactic Ablative Body Radiotherapy (SABR) programs and his current research efforts focus on how radiation can alter the course of metastatic disease and (outside of cancer) whether radiation is able to treat heart arrhythmias.
Kristen Campbell, PT, BSc, PhD
Director, Clinical Exercise Physiology Laboratory
University of British Columbia
Kristin Campbell, BSc, PT, PhD is a licensed physical therapist and a Professor in the Department of Physical Therapy at the University of British Columbia in Vancouver, Canada. She also an Affiliated Scientist in the Cancer Control Program at the BC Cancer Research Institute.
Her research focus is on the role of exercise in cancer rehabilitation and survivorship has been funded by the Canadian Cancer Society Research Institute, Michael Smith Foundation for Health Research and Physiotherapy Foundation of Canada and others. She is the co-lead of the 2019 exercise guidelines for cancer survivors from the American College of Sports Medicine and in 2020 received a Distinguished Achievement Award for Overall Excellence Mid-Career from the Faculty of Medicine at UBC.
Joe Y. Chang, MD PhD FASTRO
Texas 4000 Distinguished Professor
Director of Stereotactic Ablative Radiotherapy
MD Anderson Cancer Center
Dr. Chang is a thoracic radiation oncologist with more than 30 years of clinical and research experience. He holds a tenured Texas 4000 Distinguished Professorship at MD Anderson Cancer Center. He is an appointed American Society of Radiation Oncology Fellow and has been recognized with the Best Doctors of America award. He is one of the pioneers in the field of stereotactic ablative radiotherapy (SABR) and proton therapy for lung cancer, having published more than 290 peer-reviewed articles in prestigious journals, including LANCET, Nature, JAMA, Journal of Clinical Oncology, Journal of Thoracic Oncology, and various others. His randomized study comparing surgery vs SABR in operable stage I lung cancer, concurrent proton therapy and chemotherapy in stage III lung cancer, and the implementation of intensity-modulated proton therapy (IMPT) in lung cancer were the first reported clinical studies in the world to do so. His research has helped establish the role of SABR, proton therapy, and combined immunotherapy and SABR (I-SABR) in lung cancer; currently, he is the principle investigator of a randomized study of I-SABR in early stage lung cancer. He is a voting committee member of NCCN thoracic guidelines and chairs both the international proton therapy PTCOG thoracic and American Radium Society Thoracic AUS committees. Additionally, on behalf of national and international societies, Dr. Chang has led several important consensus statements that have significantly impacted in radiation oncology community about SABR, proton therapy in lung cancer, IMPT in moving thoracic cancers, management of small cell lung cancer, oligometastasis, and re-irradiation of thoracic cancer.
Peter Ellis, MBBS, MMed(Clin Epi), PhD, FRACP, FRCPC
Professor, Dept of Oncology and Health Research Methods
Division Head of Medical Oncology
Juravinski Cancer Centre
Dr Ellis is a Professor in the Departments of Oncology and Health Research Methods, Evidence & Impactat McMaster University. He is also Division Head of Medical Oncology at the Juravinski Cancer Centre (JCC). He obtained his medical degree at the University of Sydney. He completed a Masters of Medicine (Clinical Epidemiology) and a PhD also at the University of Sydney. Dr Ellis moved to Canada in October, 2000. He is an Executive Member of the Canadian Cancer Trials Group (CCTG) Lung Disease Site Committee, and is Co-Chair of Cancer Care Ontario’s Practice Guideline Initiative, Provincial Lung Disease Site Group. He is also an investigator on several CCTG and pharmaceutical industry-sponsored multicentre phase III clinical trials in breast and lung cancer.
Kristen Haase, RN PhD
Assistant Professor at the School of Nursing
University of British Columbia,
Kristen Haase, RN PhD (she/her/hers) is an Assistant Professor at the School of Nursing at UBC and an affiliated researcher in the Fraser Health Authority. Her research program centres on supporting older adults as they manage cancer, chronic disease, and wellbeing, in domains of symptom science, self-management, and technology-enabled interventions.
Kevin Jao, MD, MSc, FRCPC
Hôpital du Sacré Coeur de Montréal
Dr Jao is an adjunct professor at the Université de Montréal and a hemato-oncologist at the Hôpital du Sacré Coeur de Montréal. He is the medical oncology lead of the thoracic oncology team.
He has a master’s degree in Immunology and HIV from McGill University. He went on to obtain his medical degree from the Université de Montréal, and specialized in internal medicine, hematology and medical oncology. He completed a fellowship in thoracic oncology at the Princess Margaret Cancer Center.
He is the current director of research in hematology and oncology at Sacré Coeur Hospital.
Rana Jin, RN, DNP, CON(C)
Clinical Nurse Specialist, Older Adults with Cancer Clinic (OACC)
Princess Margaret Cancer Center
Rana is a clinical nurse specialist in the Older Adults with Cancer Clinic at the Princess Margaret Cancer Centre, Canada, and has had the privilege of being a part of this clinic since its existence in 2015. Rana recently finished her Doctorate of Nursing Practice in 2021, and her thesis focused on proactive follow-up for older adults with cancer after systemic therapy in order to decrease unplanned health care utilization. Rana has her Canadian Certification in Oncology Nursing, is an active member of the Canadian Association of Nurses in Oncology (CANO) and the International Society of Geriatric Oncology (SIOG). Rana was awarded the 2019 Boehringer Ingelheim Oncology Nurse of the Year Award, Canada, and the 2019 Saul and Esther Baker Award Recipient for her outstanding contributions in the care of older patients across Mount Sinai and the University Health Network Hospitals.
Catherine Labbé, MD
Head, Respiratory Medicine Service Dept.
Institut universitaire de cardiologie et de pneumologie
Professor of Medicine
Dr. Catherine Labbé is the Head of the Respiratory Medicine Service at the Institut universitaire de cardiologie et de pneumologie de Québec, and Professor of Medicine at Laval University. She completed a Clinical research fellowship in Thoracic Oncology at Princess Margaret Cancer Centre in Toronto from 2014 to 2016. She has several research interests including targeted therapies, immuno-oncology, treatment toxicities and patient-reported outcome measures.
Janessa, Laskin, MD, FRPCP
Department of Medicine
University of British Columbia
Dr Laskin is a clinical Associate Professor in the Department of Medicine at the University of British Columbia and an active member of the Medical Oncology staff at BC Cancer in Vancouver. Her clinical and research interests have primarily focused on thoracic oncology and cancer genomics. Among other activities, she is currently on the ASCO panel to develop guidelines for the treatment of SCLC.
Magali Lecavalier-Barsoum, M.D., FRCP(C)
Assistant Professor, Oncology Department
Department of Oncology, Division of Radiation Oncology
Jewish General Hospital
Dr. Lecavalier-Barsoum did her residency at McGill and a 2-year fellowship and Masters at the Princess Margaret Hospital in Toronto. She works at the Jewish General Hospital since 2017, where she treats thoracic, gyne, GI and breast malignancies. She is the site director of the Radiation Oncology Program at the Jewish General Hospital and the fellowship co-director. She is involved in clinical and basic science research projects
Benjamin Lok, MD FRCPC
Clinician-Scientist, Radiation Medicine Program, Princess Margaret Cancer Centre
Assistant Professor, Department of Radiation Oncology, Institute of Medical Science, and Medical Biophysics, University of Toronto
Clinician-Scientist, Research Institute, Princess Margaret Cancer Centre
Dr. Benjamin Lok is a Clinician-Scientist and Staff Radiation Oncologist at the Princess Margaret Cancer Centre in Toronto, Canada. At the University of Toronto, Dr. Lok is appointed as an Assistant Professor in the Department of Radiation Oncology, Department of Medical Biophysics, and the Institute of Medical Science.
Dr. Lok obtained his MD in 2012 from New York University and subsequently completed his Radiation Oncology residency training in 2017 at Memorial Sloan Kettering Cancer Center. Dr. Lok has received extensive training in laboratory research; initially mentored by Dr. Simon Powell on DNA damage and repair response. Dr. Lok then conducted work in Dr. Charles Rudin’s lab where he investigated the role of PARP and EZH2 inhibitors in small cell lung cancer and their utility as radiosensitizers. Dr. Lok has published his work in journals such as Cancer Cell, Journal of Thoracic Oncology, Nature Communications, Oncogene, and Clinical Cancer Research.
Since establishing his independent lab in 2017, Dr. Lok has received multiple peer-review grants including a Career Development Award from the CCF of ASCO, a Research Grant from the Ontario Molecular Pathology Research Network (OMPRN)/Ontario Institute for Cancer Research (OICR), a Young Investigator Award and an Academy Award from the International Association for the Study of Lung Cancer (IASLC), an Operating Grant from the Cancer Research Society (CRS), a grant from the John R. Evans Leaders Fund (JELF) from the Canada Foundation for Innovation (CFI), a Project Grant from the Canadian Institutes of Health Research (CIHR), and a U01 grant from the National Cancer Institute (NCI)/National Institutes of Health (NIH).
He has been the recipient of many awards, including the Young Investigator Award (2018) from the International Association for the Study of Lung Cancer (IASLC), and a Career Development Award in (2018 )and Young Investigator Award (2016) from the American Society of Clinical Oncology (ASCO) and the William C. Rippe Award for Distinguished Research in Lung Cancer (2019) from the Lung Cancer Research Foundation (LCRF).
Dr. Lok’s laboratory and clinical research focus is directed towards improving outcomes for lung cancer patients by understanding mechanisms of treatment resistance and developing novel therapeutic strategies.
Billy W. Loo, Jr., M.D., Ph.D
Professor of Radiation Oncology
Dept. of Radiology, Stanford (MIPS)
Physician-Scientist, Radiation Oncologist, Bioengineer
Director, Thoracic Radiation Oncology Program
Billy W. Loo, Jr., M.D., Ph.D. is a Professor of Radiation Oncology, a member of the
Molecular Imaging Program at Stanford (MIPS) in the Department of Radiology, and a
member of the Stanford Cancer Institute, in the School of Medicine. He is a physician scientist Radiation Oncologist and Bioengineer who directs the Thoracic Radiation Oncology Program at Stanford.
His clinical specialties are state-of-the-art radiation therapy for lung/thoracic cancers,
including stereotactic ablative radiotherapy (SABR) and 4-D image-guided radiation
therapy for lung tumors. Dr. Loo is a recognized expert in thoracic cancers serving on
multiple national committees (including as writing member, chair, or vice-chair) that
publish clinical guidelines on the treatment of lung cancer and other thoracic
malignancies, including the National Comprehensive Cancer Network (NCCN),
American College of Radiology (ACR), and American Society of Radiation Oncology
His clinical research is in clinical trials and implementation of new treatment
techniques for lung cancer, and development of new medical imaging methods for
measuring organ function and predicting response to cancer treatment. As part of this
work, he leads a clinical and preclinical research program in molecular imaging,
particularly using novel PET tracers for tumor hypoxia (EF5), tumor proliferation (FLT),
and neuroinflammation (PBR06). He also co-leads clinical trials of novel applications of
SABR including treatment of pulmonary emphysema and cardiac arrhythmias.
Since conceiving of a fundamentally new approach to delivering ultra-rapid, ultra precise radiation therapy, pluridirectional high-energy agile scanning electronic
radiotherapy (PHASER), Dr. Loo’s major laboratory research focus has been to co-lead a
collaborative effort between the Stanford Cancer Institute and SLAC National
Accelerator Laboratory to develop PHASER into a transformative yet clinically practical
technology. This program comprises both technology development and fundamental
research on the radiobiology of extremely rapid FLASH radiation therapy to optimize
the biological therapeutic index.
Dr. Loo received his MD from University of California, Davis and his PhD in
Bioengineering from University of California, San Francisco and Berkeley. He completed
his Radiation Oncology residency training at Stanford University. He is certified by the
American Board of Radiology in Radiation Oncology.
Alexander Louie, MD, PhD, M.Sc., FRCPC
Department of Radiation Oncology
University of Toronto
Dr. Louie’s academic focus is the use of comparative effectiveness research in lung, kidney and oligometastatic cancers. He has expertise in clinical trials, patient-reported outcomes, population databases, decision analyses, health economics and technological appraisals.
Basil S. Nasir, MD, M.B.B.Ch
Thoracic Surgeon, CHUM
After completing a general surgery residency at the Mayo Clinic in Minnesota, and in cardiothoracic surgery at the University of Alabama in Birmingham, Dr. Nasir completed a Fellowship at the CHUM in advanced minimally invasive endoscopy techniques. He subsequently completed a second Fellowship at Duke University in lung transplant.
Dr. Nasir was hired by the CHUM in 2018, where he has been working as a thoracic surgeon, specializing in the treatment of malignant and benign diseases of the lung, esophagus and mediastinum in addition to lung transplantation.
Aliyah Pabani MD, FRCPC
Clinical Assistant Professor
Tom Baker Cancer Center
Dr. Pabani is a Medical Oncologist at the Tom Baker Cancer Centre, Calgary, AB and is currently appointed as a Clinical Assistant Professor in the Department of Medicine at the University of Calgary. She completed her Internal Medicine and Medical Oncology Training at the University of Alberta and a fellowship in Thoracic Oncology and Immunotherapy at Columbia University in New York City.
Yu Shyr, PhD
Harold L. Moses Chair in Cancer Research
Chair, Department of Biostatistics
Director, Vanderbilt Center for Quantitative Sciences (VCQS)
Director, Vanderbilt Technologies for Advanced Genomics Analysis and Research Design
Professor of Biostatistics, Biomedical Informatics, and Health Policy
Vanderbilt University Medical Center
Yu Shyr received his Ph.D. in biostatistics from the University of Michigan (Ann Arbor) in 1994 and subsequently joined the faculty at Vanderbilt University School of Medicine. Dr. Shyr is a Fellow of the American Statistical Association (ASA), an elected fellow of the American Association for the Advancement of Science (AAAS). He has published more than 500 peer-reviewed papers in a variety of journals (h-index = 111). Dr. Shyr was the member of the US National Academy of Medicine (IOM) Committee on Policy Issues
in the Clinical Development of Biomarkers for Molecularly Targeted Therapies and a US Food and Drug Administration (FDA) advisory committee voting member. He has served as a member of the US National Cancer Institute (NCI) Developmental Therapeutics Study Section, Cancer Immunopathology and Immunotherapy Study Section and the Population and Patient-oriented Training Study Section. Dr. Shyr was the co-course director for the AACR/ASCO Methods in Clinical Cancer Research Vail Workshop. He is the Associate Editor for JAMA Oncology, and Journal of Thoracic Oncology (JTO). In addition, Dr. Shyr is the principle investigator of the NCI U01 grant of Barrett’s esophagus translational research network coordinating center (BETRNetCC), and the co-course director for the 2021 BMSF-AACR Design and Implementation of
Clinical Trials Workshop. Dr. Shyr’s current research interests focus on developing statistical bioinformatic methods for analyzing next-generation sequencing data based on single cell technology including a series of papers on estimating the sample size requirements for studies conducting sequencing analysis and novel
statistical methods for analyzing the single-cell RNA sequencing (scRNA-seq) data.
Alexander Sun MD, FRCPC
Department of Radiation Oncology
University of Toronto
Dr. Alex Sun is a radiation oncologist and the Lung Cancer Site Group Leader of the Radiation Medicine Program at Princess Margaret Cancer Centre with a substantial track record of clinical research in thoracic radiation oncology. He has held national and international leadership positions in several research, policy and educational organizations, including academic clinical trials groups. His research interests include the development of clinical trials to improve outcomes in lung cancer patients through the integration of Positron Emission Tomography (PET) imaging in the management of lung cancer and to define the role of prophylactic cranial irradiation (PCI). More recently, his research interests have also incorporated the combining of immunotherapy (I/O) with radiation.
Dr. Sun is currently the Addie MacNaughton Chair in Thoracic Radiation Oncology at Princess Margaret Cancer Centre/University of Toronto and is an Associate Professor, in the Department of Radiation Oncology, University of Toronto. He is also the NRG Oncology Principal Investigator for Princess Margaret Cancer Centre and is a member of the NRG Oncology Lung Cancer Steering Committee as well as the Co-Chair of the CCTG Lung Disease Site Committee.
Paul Wheatley-Price, BSc, MBChB, FRCP (UK), MD
Department of Medicine
University of Ottawa
Ottawa Hospital Cancer Centre
Dr. Paul Wheatley-Price is Associate Professor in the Department of Medicine at the University of Ottawa, and a medical oncologist at The Ottawa Hospital Cancer Centre, specializing in the treatment of thoracic malignancies and carcinoma of unknown primary. He is the medical oncology lead for the lung cancer disease site group.
From 2016 – 2021 Dr. Wheatley-Price served as President of Lung Cancer Canada, and he remains active in lung cancer advocacy.
Dr. Wheatley-Price attended medical school in the UK, at the University of St. Andrews (1991-1994) and the University of Manchester (1994 – 1997). He received specialist medical oncology training in Wellington, New Zealand, in London at the Royal Free Hospital, Guy’s and St. Thomas’ Hospitals and St. George’s Hospital, and as a Fellow in Lung Cancer Research at Princess Margaret Cancer Centre in Toronto.
He has been in Ottawa since 2009.
Pan-Chyr Yang, MD, PhD
Department of Internal Medicine
National Taiwan University Hospital
National Taiwan University
Dr. Yang is Chair Professor of National Taiwan University College of Medicine. He was the former President of National Taiwan University. His major research interests are lung cancer genomics and precision lung cancer therapy. He was elected as member of Academia Sinica in 2006, the World Academic of Science in 2008, the National Academy of Inventors of USA in 2015 and the International Association for the Study of Lung Cancer (IASLC) the 2020Joseph W. Cullen Prevention/Early Detection Distinguished Service Award because of his contributions in leading the translational research in precision cancer medicine and the implementation of lung cancer screening in never smoker, which significantly improved the survival of lung cancer patients in Taiwan. Their research group identified the proteogenomics signatures of pathogenesis and progression of never smoker lung cancer in East Asian population. They successfully established new platforms of theranostic applications of aptamer and smart targeting of cancer stem cell and tumor microenvironment that may provide new strategy to improve treatment outcome of lung cancer patients.